NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Grip,

Thank you for reposting your opinion again.

The company is still very small, but the leadership are formidable and tenacious. The independent peer review took a long time too, but it was successfully completed and published in JAMA Oncology, and it is an asset as we move further into the regulatory process.

The CEO has been quite an effective and successful leader of a small clinical-stage biotech. She is responsible for leading the company to the point where NWBO now has a valuable cell-based platform technology that has completed all three phases of clinical investigation. PD1 combo and platform potential represent additional value beyond the P3...

DCVax-L has been investigated in other clinical trials and is currently being studied in combo with PD1 blockade at UCLA, and this novel technology will be studied in other combos and other cancers too. The CEO put the company in a position where these forthcoming developments are possible. After successful commercialization, we can learn a lot more about this technology as a platform.

The leadership team have positioned the company well globally and they have secured a solid comprehensive worldwide patent portfolio. The results presented in the JAMA publication represent the greatest prospective value that NWBO has ever had since the company was founded.

In my opinion, JAMA Oncology put Northwest Bio on the radar of institutional investors, and MHRA will likely be the next tipping point.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171297915

https://www.lifespan.org/centers-services/lifespan-cancer-institute




https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers